Factors related to axillary lymph node metastasis in T1 breast carcinoma

Oncology Reports

Volumn 5, Issue 2, 1998, Pages 459-462

  Singh, Yogendra ^a   Nambu, Hiroyuki ^a   Yoshizawa, Katsuhiko ^a   Hatano, Takehiko ^a   Hioki, Koshiro ^a   Tsubura, Airo ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Axillary lymph node; Bcl 2; Breast cancer; Ki 67; Metastasis; Microvessel count; T1

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67; PROGESTERONE RECEPTOR; PROTEIN BCL 2;

ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MICROVASCULATURE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; TUMOR VOLUME;

EID: 0031912030     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.2.459     Document Type: Article

References (25)

1. Tominaga S and Kuroishi T: Epidemiology of breast cancer in Japan. Breast Cancer 2: 1-7, 1995.
2. Tabár L, Fagerberg G, Day NE, Duffy SW and Kitchin RM: Breast cancer treatment and natural history: new insights from results of screening. Lancet 339: 412-414, 1992.
3. Carter CL, Allen C and Henson DE: Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 63: 181-187, 1989.
4. Holmberg L, Lindgren A, Nordén T, Adami H-O and Bergström R: Age as a determinant of axillary node involvement in invasive breast cancer. Acta Oncol 31: 533-538, 1992.
5. Chadha M, Chabon AB, Friedmann P and Vikram B: Predictors of axillary lymph node metastases in patients with T1 breast cancer. Cancer 73: 350-353, 1994.
6. Giuliano AE, Barth AM, Spivack B, Beitsch PD and Evans SW: Incidence and predictors of axillary metastasis in T1 carcinoma of the breast. J Am Coll Surg 183: 185-189, 1996.
7. Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
8. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
9. Horak ER, Leek R, Klenk N, Lejeune S, Smith K, Stuart N, Greenall M, Stepniewska K and Harris AL: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340: 1120-1124, 1992.
10. Singh Y, Inoue K, Kawanishi H, Hioki K, Horio T, Shikata N, Uemura Y and Tsubura A: Angiosarcoma of the breast: immunohistochemical demonstration of steroid receptors and literature review. Breast Cancer 3: 125-129, 1996.
11. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F and Veronesi U: The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
12. Sierra A, Lloveras B, Castellsagué X, Moreno L and Garciá-Ramirez M: Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 60: 54-60, 1995.
13. Harris JR, Lippman ME, Veronesi U and Willett W: Breast cancer. N Engl J Med 327: 473-480, 1992.
14. 0) breast carcinoma. J Clin Oncol 7: 355-366, 1989.
15. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 1992.
16. Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L and von Smitten K: Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 68: 579-583, 1993.
17. Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JFR, Blarney RW and Nicholson RI: Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59: 943-947, 1989.
18. Gasparini G, Pozza F, Bevilacqua P, Meli S, Boracchi P, Reitano M, Santini G, Marubini E and Sainsbury JRC: Growth fraction (Ki-67 antibody) determination in early-stage breast carcinoma: histologic, clinical and prognostic correlations. Breast 1: 92-99, 1992.
19. Charpin C, Andrac L, Vacheret H, Habib MC, Devictor B, Lavaut MN and Toga M: Multiparametric evaluation (SAMBA) of growth fraction (Monoclonal Ki-67) in breast carcinoma tissue sections. Cancer Res 48: 4368-4374, 1988.
20. Barnard NJ, Hall PA, Lemoine NR and Kadar N: Proliferative index in breast carcinoma determined in situ by Ki-67 immunostaining and its relationship to clinical and pathological variables. J Pathol 152: 287-295, 1987.
21. Weikel W, Beck T, Mitze M and Knapstein PC: Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat 18: 149-154, 1991.
22. Singh Y, Shikata N, Kiyozuka Y, Nambu H, Morimoto J, Kurebayashi J, Hioki K and Tsubura A: Inhibition of tumor growth and metastasis by angiogenesis inhibitor TNP-470 on breast cancer cell lines in vitro and in vivo. Breast Cancer Res Treat 45: 15-27, 1997.
23. Bosari S, Lee AKC, Delellis RA, Wiley BD, Heatley GJ and Silverman ML: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23: 755-761, 1992.
24. Toi M, Kashitani J and Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55: 371-374, 1993.
25. Leek RD, Kaklamanis L, Pezzella F, Gatter KC and Harris AL: bcl-2 in normal human breast and carcinoma, association with estrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer. Br J Cancer 69: 135-139, 1994.